FDA approves CRISPR-based sickle cell treatment in historic decision
Dec. 8 was a historic day for the sickle cell community and CRISPR technology, as the U.S. Food and Drug Administration (FDA) approved two milestone treatments: Casgevy, made by Vertex Pharmaceuticals, and Lyfgenia, made by bluebird bio.
